Physician’s Briefing—September 1, 2014
During the conference, Mary B. Goldring, M.D., of the Hospital for Special Surgery in New York City, led a symposium focused on bone and inflammation. In a talk presented during the symposium, Georg Schett, M.D., of the St. Vincent Hospital in Vienna, reviewed several of the novel mechanisms involved in pathologic bone loss in rheumatoid arthritis, including the unique role of anti-citrullinated protein antibodies (ACPAs) and rheumatoid factors, in directly regulating osteoclastogenesis.
"Schett highlighted that targeting inflammation with disease modifying therapies can block or attenuate local articular as well as systemic bone resorption. He also pointed out that therapies that directly target osteoclastogenesis and/or osteoclast-mediated bone resorption can inhibit articular bone erosions even in the absence of effects on inflammation," said Goldring.
Read the full article on physiciansbriefing.com.